Cloudbreak Pharma Releases First ESG Report: Sets 2027 Resource-Efficiency Targets and Reports 2025 GHG Emissions of 533.06 tCO₂e

Bulletin Express03-31 23:04

Cloudbreak Pharma published its inaugural Environmental, Social and Governance Report, detailing 2025 performance metrics, governance arrangements and mid-term sustainability goals. Key takeaways follow.

Strategic Targets • Resource efficiency objectives aim to cut electricity, water and hazardous-waste generation per employee by 2 % by end-2027, using 2025 as the baseline. • A four-tier governance structure—Board, EHS Manager, ESG Working Group and EHS Teams—oversees target delivery and climate-risk integration.

Climate Metrics (2025) • Total GHG emissions: 533.06 tCO₂e, comprising 76.58 tCO₂e Scope 2 (purchased electricity) and 456.48 tCO₂e Scope 3 (business travel and employee commuting). • No material Scope 1 emissions were recorded, consistent with the company’s laboratory-focused operating model.

Operational Footprint (2025) • Electricity use: 866,769 kWh, or 14,446 kWh per employee. • Water consumption: 680.18 tons, or 11.33 tons per employee. • Hazardous waste: 9.99 tons (0.17 tons per employee). • Non-hazardous waste: 4.71 tons (0.08 tons per employee). All hazardous waste was treated off-site by licensed third parties.

Workforce Statistics • Headcount: 61 (55 % female). • Zero work-related injuries or lost workdays in 2025. • Turnover rate: 17 % overall; 22 % for males and 12 % for females. • Training: 75 % of employees trained, averaging 12.5 hours each.

Supply Chain Oversight • Total suppliers: 277, with 50 % located in Mainland China or Hong Kong, 22 % in North America and the remainder across Europe, Asia and Oceania. Supplier assessments cover service quality, technical capability, legal compliance, safety and environmental performance.

Community & Ethics • No product recalls, data-privacy breaches or concluded corruption cases were reported during the year. • Donations were made to local community initiatives; employees are encouraged to participate in voluntary activities.

Outlook The report signals Cloudbreak Pharma’s intention to strengthen ESG disclosure as clinical programmes advance toward commercialisation, with an emphasis on product quality, patient privacy and enhanced climate-risk analysis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment